The pharmacotherapy of insomnia has expanded considerably beyond benzodiazepines since the 1990s, driven both by recognition of the limitations of benzodiazepine hypnotics — suppression of restorative sleep architecture, dependence liability, next-day cognitive impairment — and by advances in understanding the neurobiology of sleep-wake regulation. Three mechanistically distinct drug classes have emerged as alternatives: the non-benzodiazepine hypnotics ("Z-drugs"), which retain GABA-A receptor (GABA-A) modulation but with claimed subtype selectivity; the melatonin receptor agonists, which exploit circadian rhythm pathways; and the orexin receptor antagonists, which target the wake-promoting hypocretin/orexin system.1 2 Each class carries a distinct pharmacological profile with meaningful clinical implications for drug selection, adverse effect management, and appropriate patient matching.
This module examines the mechanisms, pharmacokinetics, clinical profiles, and safety considerations of these three classes in the context of insomnia pharmacotherapy, with particular attention to practical prescribing decisions, comparative efficacy data, and the regulatory and safety signals that inform current clinical practice.
Insomnia disorder — defined as difficulty initiating or maintaining sleep, or early morning awakening, associated with daytime impairment, occurring at least three nights per week for at least three months — is among the most prevalent medical complaints in clinical practice, affecting an estimated 10–15% of adults with chronic insomnia disorder and 30–35% with occasional insomnia symptoms.3 The condition is strongly comorbid with depression, anxiety, chronic pain, and cardiovascular disease, and bidirectional relationships between insomnia and these comorbidities complicate management.
Current evidence-based guidelines from the American Academy of Sleep Medicine (AASM) and the American College of Physicians (ACP) consistently identify cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment for chronic insomnia disorder.3 Pharmacotherapy is indicated as adjunctive treatment when CBT-I is unavailable, has failed, or when rapid symptom control is needed. Among pharmacological options, the AASM 2017 clinical practice guideline provides specific recommendations that differ by sleep complaint: sleep-onset insomnia versus sleep-maintenance insomnia require different pharmacological approaches, and agent selection is further guided by comorbidities, polypharmacy risk, patient age, and abuse potential.3
For clinicians, the practical decision tree for hypnotic selection involves: (1) characterizing the insomnia complaint (onset vs. maintenance vs. mixed); (2) identifying contraindications and risk factors for specific agents; (3) selecting the agent with the most targeted mechanism for the complaint; and (4) establishing a clear treatment duration expectation with the patient from the outset.
AGENTS AND STRUCTURAL OVERVIEW: The Z-drugs — zolpidem, zaleplon, and eszopiclone — are structurally heterogeneous compounds (none is a 1,4-benzodiazepine) that nonetheless share the benzodiazepine binding site on the GABA-A receptor (GABA-A). Their colloquial grouping reflects both the initial letter of each drug name and their marketing position as pharmacologically distinct from classical benzodiazepines. A fourth agent, zopiclone (not available in the US but widely used elsewhere), is the racemic precursor of eszopiclone.
RECEPTOR SELECTIVITY — THE ALPHA-1 CLAIM: The principal pharmacological distinction claimed for Z-drugs is relative selectivity for GABA-A receptors containing the α1 subunit, which mediates sedation, over α2/α3 subunits, which mediate anxiolysis and muscle relaxation.4 In theory, α1 selectivity would produce sedation without anxiolytic, muscle relaxant, or anticonvulsant effects — a more targeted hypnotic profile. In practice, this selectivity is dose-dependent and partial: at therapeutic doses, zolpidem demonstrates meaningful α1 preference, while at higher doses this selectivity is diminished and benzodiazepine-like effects emerge.4 Eszopiclone has less pronounced α1 selectivity than zolpidem. The clinical consequence is that Z-drugs do not fully eliminate the concerns associated with GABA-A modulation — particularly with higher doses, chronic use, or in susceptible populations.
ZOLPIDEM: Zolpidem (Ambien, Ambien CR, Intermezzo, Edluar, Zolpimist) is the most widely prescribed hypnotic in the United States and globally. It is FDA-approved for short-term treatment of insomnia and exists in multiple formulations with distinct pharmacokinetic profiles:
Immediate-release (IR) zolpidem (5–10 mg): Onset 30 minutes, duration 6–8 hours, half-life approximately 1.5–2.5 hours. Primarily addresses sleep-onset insomnia. The standard dose was revised in 2013 by the FDA to 5 mg for women and 5–10 mg for men, based on pharmacokinetic data showing higher and more prolonged plasma levels in women at the 10 mg dose, resulting in next-morning impairment at blood concentrations sufficient to affect driving.5
Extended-release (ER) zolpidem (6.25–12.5 mg): Designed for sleep-maintenance insomnia with a biphasic release profile extending duration. Carries greater next-day sedation risk than IR.
Sublingual low-dose zolpidem (1.75 mg women, 3.5 mg men, Intermezzo): Approved for middle-of-the-night awakening, for use only when at least 4 hours of sleep time remain.
Metabolism: Zolpidem undergoes hepatic CYP3A4 (cytochrome P450 3A4) metabolism (with minor CYP1A2 (cytochrome P450 1A2) and CYP2C9 (cytochrome P450 2C9) contributions) to inactive metabolites. CYP3A4 inducers (rifampin, carbamazepine) markedly reduce plasma levels; CYP3A4 inhibitors (azole antifungals, certain macrolides) increase levels and duration of effect.
ZALEPLON: Zaleplon (Sonata) has the shortest half-life of the three Z-drugs (approximately 1 hour), making it uniquely suited for sleep-onset insomnia in patients who need to fall asleep quickly or who wake in the middle of the night and need to return to sleep with at least 4 hours of sleep time remaining (due to its very short duration, it can be taken with minimal next-day residual effect if sufficient sleep time remains). It is metabolized primarily by aldehyde oxidase to inactive metabolites, with minor CYP3A4 involvement.6 Standard dose is 5–10 mg. The very short half-life also means minimal residual effect is expected if taken at the recommended time, but it provides no benefit for sleep-maintenance insomnia.
ESZOPICLONE: Eszopiclone (Lunesta) is the S-enantiomer of racemic zopiclone and has the longest half-life of the three Z-drugs (approximately 6 hours, extended to 9 hours in elderly patients).6 Unlike zolpidem and zaleplon, eszopiclone is FDA-approved for both sleep-onset and sleep-maintenance insomnia and was the first hypnotic to receive FDA approval without restriction to short-term use, based on a 6-month efficacy trial.3 It is metabolized by CYP3A4 and CYP2E1 (cytochrome P450 2E1). A distinctive adverse effect is a metallic or bitter taste reported by 17–34% of patients, which significantly affects tolerability. Standard dose is 1–3 mg; the 1 mg dose is recommended as starting dose in elderly patients.
COMPARATIVE EFFICACY AND SAFETY OF Z-DRUGS:
Sleep architecture: Unlike benzodiazepines, Z-drugs at therapeutic doses produce less suppression of slow-wave sleep (slow wave sleep (SWS)/N3), though this effect is not entirely absent. rapid eye movement (REM) sleep effects are minimal at standard doses.6 This theoretically less disruptive effect on restorative sleep architecture was a key marketing distinction, though clinical outcomes data demonstrating meaningful superiority in sleep quality over benzodiazepines are limited.
Abuse and dependence potential: Despite claims of reduced abuse liability, Z-drugs — particularly zolpidem — carry Schedule IV controlled substance status in the US and have documented abuse potential.7 Tolerance and dependence do occur with chronic use, particularly with higher doses. Physical dependence is less severe than with classical benzodiazepines but is clinically real. A rebound insomnia phenomenon upon discontinuation is well-documented.
COMPLEX SLEEP BEHAVIORS — A CRITICAL SAFETY CONCERN: In 2019, the FDA issued a black box warning for all Z-drugs (and other sedative-hypnotics) regarding the risk of complex sleep behaviors, including sleepwalking, sleep-driving, engaging in activities while not fully awake with no memory of the event the following morning.7 These behaviors have resulted in serious injuries and deaths. Risk factors include higher doses, concomitant CNS depressants, and alcohol use. Patients experiencing any complex sleep behavior must immediately discontinue the medication. The FDA mandated that manufacturers add contraindications for use in patients who have experienced complex sleep behaviors with any sedative-hypnotic.
NEXT-DAY IMPAIRMENT: All Z-drugs carry risk of next-morning cognitive and psychomotor impairment, particularly with higher doses, extended-release formulations, and in elderly patients. The 2013 FDA dose revision for zolpidem was specifically driven by driving simulation and road driving studies demonstrating impairment at standard 10 mg doses in women, with blood levels still above the level associated with impairment in the morning after bedtime use.5 This has broader implications: any patient taking a Z-drug should be counseled that next-morning activities requiring full alertness — including driving — may be impaired, and lower doses should be used whenever clinically feasible.
SPECIAL POPULATIONS — Z-DRUGS:
Elderly: All Z-drugs are included in the American Geriatrics Society (AGS) Beers Criteria as medications to avoid in older adults due to increased sensitivity to CNS effects, elevated fall and fracture risk, and risk of cognitive impairment.8 If a hypnotic is necessary in an elderly patient, the lowest effective dose of a shorter-acting agent (low-dose zolpidem IR or zaleplon) is preferred, with explicit counseling on fall risk.
Hepatic impairment: CYP3A4-dependent metabolism of zolpidem and eszopiclone is reduced in hepatic disease, increasing half-life and risk of accumulation. Zaleplon's aldehyde oxidase pathway is less affected by moderate hepatic disease but caution is still warranted.
THE MELATONIN SYSTEM AND CIRCADIAN RHYTHM PHARMACOLOGY: Melatonin is synthesized and secreted by the pineal gland in a circadian pattern under the control of the suprachiasmatic nucleus (SCN) of the hypothalamus. Secretion rises in the evening in response to diminishing light input via the retinohypothalamic tract, peaks in the early hours of the night (approximately 2–4 AM), and declines toward morning. The primary physiological role of melatonin is as a temporal signal encoding darkness — it does not generate sleep directly but serves as a chronobiological cue that facilitates phase-setting of the sleep-wake cycle.9 Two melatonin receptor subtypes mediate its pharmacological effects: melatonin receptor type 1 (MT1) receptors, which suppress SCN neuronal activity and promote the inhibition of alerting signals; and melatonin receptor type 2 (MT2) receptors, which are involved in phase-shifting the circadian clock.
RAMELTEON (Rozerem): Ramelteon is a selective agonist at MT1 and MT2 receptors with substantially higher affinity for these receptors than endogenous melatonin (6- to 3-fold greater affinity at MT1 and MT2, respectively).9 It has no affinity for GABA-A receptors (GABA-A), serotonin receptors, dopamine receptors, opioid receptors, or any of the receptors through which classical CNS depressants act. This mechanistic distinction has important clinical consequences: ramelteon is not a controlled substance, has no abuse or dependence potential established in clinical trials, does not produce cognitive or psychomotor impairment at recommended doses, and does not carry the complex sleep behavior warning of Z-drugs.
Pharmacokinetics: Ramelteon is rapidly absorbed (Tmax approximately 45 minutes) and undergoes extensive first-pass hepatic metabolism via CYP1A2 (cytochrome P450 1A2) (primary) and CYP2C9 (cytochrome P450 2C9) and CYP3A4 (cytochrome P450 3A4) (minor).9 Its major active metabolite M-II has lower receptor affinity but significantly longer half-life (2–5 hours) than the parent compound (1–2.6 hours). Strong CYP1A2 inhibitors (fluvoxamine) dramatically increase ramelteon plasma levels — the combination is contraindicated. Dose is 8 mg taken 30 minutes before bedtime; it should not be taken with or after a high-fat meal (delays Tmax).
Clinical efficacy and indications: Ramelteon is FDA-approved for sleep-onset insomnia. Clinical trials demonstrate consistent reductions in subjective and objective sleep onset latency (typically 10–20 minutes), with modest effects on total sleep time and no significant effect on sleep maintenance.9 Effect sizes for sleep onset are smaller than those reported for benzodiazepines and Z-drugs in direct comparison, which limits its utility in patients with severe sleep-onset insomnia. Its primary niche is in patients where avoiding CNS-depressant effects is paramount: elderly patients, those with a history of substance use disorders, patients on CNS depressants where adding a GABA-active agent carries unacceptable risk, and patients where a non-scheduled medication simplifies prescribing.
An additional approved indication is treatment of circadian rhythm sleep-wake disorder, non-24-hour type (free-running type) in totally blind individuals — a condition in which the absence of light input to the SCN leads to progressive drift of the circadian clock. This indication is unique among approved hypnotics.
Adverse effects: Ramelteon is generally well tolerated. The most relevant adverse effects include somnolence, fatigue, and elevated prolactin levels and decreased testosterone levels with chronic use, mediated by melatonin receptor activity on hypothalamic-pituitary axis regulation.9 This endocrine effect is not commonly symptomatic at the 8 mg clinical dose but warrants awareness in patients with pre-existing hormonal conditions or those taking hormonal medications.
TASIMELTEON (Hetlioz): Tasimelteon is a selective MT1/MT2 agonist FDA-approved specifically for non-24-hour sleep-wake disorder in totally blind individuals and, more recently, for nighttime sleep disturbances in Smith-Magenis syndrome. Its pharmacological profile is similar to ramelteon with MT1 and MT2 agonism and no GABA-A receptor activity. Standard dose is 20 mg taken before bedtime at the same time each night. CYP1A2 is the primary metabolic pathway; CYP3A4 is secondary. Strong CYP1A2 inhibitors (fluvoxamine) should be avoided.10 Tasimelteon's clinical use is restricted to these specific circadian disorder indications; it is not approved for general insomnia disorder and is not used in that context.
OVER-THE-COUNTER MELATONIN: While not a pharmacological agent in the prescription sense, over-the-counter (OTC) melatonin is widely used by patients and warrants mention. Exogenous melatonin at low doses (0.3–1 mg) taken 1–2 hours before desired sleep time is supported by moderate-quality evidence for circadian phase-shifting applications (jet lag, shift work disorder, delayed sleep-phase disorder) and has a favorable safety profile. Higher doses (1–10 mg, as commonly sold) produce supraphysiologic melatonin levels with uncertain benefit over low doses and are not recommended by most sleep medicine guidelines.
THE OREXIN SYSTEM — WAKE PROMOTION AND ITS THERAPEUTIC EXPLOITATION: Orexins (also called hypocretins) are neuropeptides produced exclusively by neurons in the lateral hypothalamus. Two orexin peptides — orexin A and orexin B — act on two G-protein-coupled receptor subtypes: orexin receptor type 1 (OX1R) (hypocretin receptor 1, with higher affinity for orexin A) and orexin receptor type 2 (OX2R) (hypocretin receptor 2, with similar affinity for both peptides).11 The orexin system is a critical stabilizer of wakefulness and of the boundary between wakefulness and sleep states. Orexinergic neurons project broadly to monoaminergic and cholinergic wake-promoting nuclei (locus coeruleus, dorsal raphe, tuberomammillary nucleus, basal forebrain), providing tonic excitatory drive that sustains arousal. Orexin neuronal activity is high during active wakefulness, low during non-rapid eye movement (NREM) sleep, and minimal during rapid eye movement (REM) sleep.
The clinical significance of the orexin system was dramatically illuminated by the discovery that narcolepsy type 1 (narcolepsy with cataplexy) is caused by selective loss of orexinergic neurons, resulting in orexin deficiency and the cardinal feature of pathological intrusion of sleep states — particularly REM-associated cataplexy — into wakefulness.11 This understanding validated the therapeutic hypothesis that blocking orexin signaling would promote sleep by removing wake-promoting drive.
SUVOREXANT (Belsomra): Suvorexant was the first orexin receptor antagonist approved by the FDA (2014) for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. It is a dual orexin receptor antagonist (DORA) with antagonist activity at both OX1R and OX2R. The mechanism — removing orexin-mediated wake drive — is distinct from all prior hypnotics, which work by enhancing inhibitory signals (GABA-A receptor (GABA-A) enhancement) or attenuating circadian arousal signals (melatonin receptors). Suvorexant facilitates the transition from wakefulness to sleep by reducing arousal rather than by direct sedation or CNS depression.11
Pharmacokinetics: Suvorexant is well absorbed orally, with Tmax approximately 2 hours (delayed if taken with a high-fat meal). It is highly protein-bound (>99%) and extensively metabolized by CYP3A4 (cytochrome P450 3A4) to an inactive metabolite. Half-life is approximately 12 hours. Strong CYP3A4 inhibitors significantly increase suvorexant exposure and are contraindicated or require dose reduction (from 20 mg to 5 mg). Strong CYP3A4 inducers reduce efficacy. Standard dosing is 10 mg at bedtime, maximum 20 mg.12
Clinical efficacy: Clinical trials demonstrate that suvorexant significantly reduces subjective sleep onset latency, increases total sleep time, and reduces wake after sleep onset (WASO) — the latter being a particularly important endpoint for sleep-maintenance insomnia.12 Suvorexant preserves normal sleep architecture, with no suppression of slow-wave sleep or REM sleep — in fact, REM sleep may be modestly increased. This preservation of sleep architecture is a meaningful pharmacological advantage over GABA-targeting agents. A 12-month safety and efficacy trial supports its use beyond the short-term period mandated for many other hypnotics.
Adverse effects and safety: Next-day somnolence is the most common adverse effect, occurring in approximately 7–10% of patients at the 20 mg dose. Sleep paralysis, hypnagogic/hypnopompic hallucinations, and cataplexy-like episodes (sudden loss of muscle tone precipitated by strong emotion, without full loss of consciousness) have been reported at a low but clinically significant frequency.12 These effects are mechanistically consistent with orexin blockade mimicking aspects of narcolepsy type 1 physiology and are dose-related. Mild worsening of sleep apnea has been reported; use in patients with severe obstructive sleep apnea (OSA) warrants caution. Suvorexant is a Schedule IV controlled substance, though its abuse liability appears lower than Z-drugs in preclinical and clinical studies.
LEMBOREXANT (Dayvigo): Lemborexant was FDA-approved in 2019 and is a DORA with slightly different binding kinetics from suvorexant — it dissociates more slowly from OX2R, which may contribute to sustained sleep maintenance effects.13 Standard doses are 5 mg and 10 mg. The 5 mg dose is recommended as the starting dose; the 10 mg dose provides greater efficacy with higher incidence of next-day somnolence. Half-life is approximately 17 hours, somewhat longer than suvorexant, with corresponding greater risk of next-day residual effects at higher doses.
In a randomized trial comparing lemborexant to zolpidem extended-release (E2006 study), lemborexant at both doses demonstrated non-inferior efficacy to zolpidem ER for sleep onset and statistically superior effects on sleep maintenance, with a more favorable next-morning driving safety profile by performance assessment.13 This comparative trial represented an important milestone in the evidence base for DORAs relative to established standard-of-care agents.
CLINICAL NICHE FOR OREXIN RECEPTOR ANTAGONISTS: DORAs are FDA-approved for both sleep-onset and sleep-maintenance insomnia, positioning them as versatile alternatives when other agents are problematic. Their practical clinical niches include: (1) patients with predominantly sleep-maintenance insomnia, where the wake-time reduction effect (WASO reduction) is well-documented; (2) patients in whom avoiding CNS depression is a priority (e.g., those with respiratory compromise, though severe OSA warrants caution given the data on sleep apnea); (3) patients where preservation of sleep architecture is clinically relevant; and (4) patients for whom the adverse effects or dependence liability of GABA-active agents are concerns.
HEAD-TO-HEAD COMPARISONS AND META-ANALYTIC DATA: A comprehensive 2022 network meta-analysis in The Lancet evaluating 30 different hypnotic agents across 154 randomized controlled trials provided the most rigorous comparative evidence to date.2 Key findings relevant to clinical practice:
For sleep onset: Benzodiazepines, Z-drugs (particularly eszopiclone and zolpidem), and suvorexant had the largest effect sizes for reducing sleep onset latency. Doxepin (a tricyclic antidepressant at sub-antidepressant doses, FDA-approved for sleep maintenance insomnia at 3–6 mg) and the DORAs also demonstrated significant efficacy. Ramelteon had the smallest effect size for sleep onset reduction.
For sleep maintenance: Suvorexant, eszopiclone, doxepin, and lemborexant demonstrated the strongest evidence for reducing wake after sleep onset and increasing total sleep time in maintenance insomnia. Zolpidem IR showed less benefit for maintenance insomnia than ER formulations.
For safety and tolerability: Ramelteon had the most favorable adverse effect profile, with no significant difference from placebo for most safety endpoints. Z-drugs and benzodiazepines carried the greatest burden of next-day impairment and, for Z-drugs, complex sleep behaviors. DORAs occupied an intermediate position — meaningful efficacy with lower GABA-associated adverse effects but unique orexin-blockade adverse effects (cataplexy-like episodes, sleep paralysis).2
CHRONIC INSOMNIA AND DURATION OF THERAPY: A fundamental clinical tension in hypnotic prescribing is the mismatch between the chronic nature of insomnia disorder and the short-term evidence base (and labeling) for most hypnotic agents. Most hypnotics are labeled for short-term use (typically 7–14 days for Z-drugs, 35 days for benzodiazepines), yet chronic insomnia by definition persists beyond 3 months. Eszopiclone and suvorexant have the most robust long-term (6–12 month) efficacy and safety data among currently approved agents.3 In practice, when pharmacotherapy extends beyond the short-term indication, the rationale should be explicitly documented, cognitive behavioral therapy for insomnia (CBT-I) should be actively recommended, and periodic reassessment of continued need should occur.
PRESCRIBING CONSIDERATIONS — COMORBID CONDITIONS:
Comorbid depression: Low-dose doxepin (3–6 mg) and trazodone (50–100 mg, off-label) are commonly used in patients with comorbid depression and insomnia; the former is FDA-approved at these doses specifically for insomnia and does not carry the anticholinergic burden of full antidepressant doxepin doses. Mirtazapine (7.5–15 mg, off-label) also promotes sleep via histamine H1 and serotonin receptor antagonism and is useful when weight gain is acceptable.
Comorbid anxiety: Benzodiazepines or Z-drugs may provide dual benefit for anxiety and insomnia, but the dependence risk must be weighed, and SSRI/SNRI initiation with temporary benzodiazepine adjunction is often preferable. Buspirone, while modestly anxiolytic, has no meaningful hypnotic activity.
Comorbid post-traumatic stress disorder (PTSD): DORAs are emerging as an attractive option given their preservation of rapid eye movement (REM) sleep (which is often dysfunctional in PTSD) and their lack of effect on trauma-related dream content, in contrast to prazosin (which reduces REM-associated nightmares) used in PTSD-specific insomnia.
Comorbid obstructive sleep apnea: Great caution is required with all hypnotics in untreated or inadequately treated obstructive sleep apnea (OSA). GABA-active agents reduce upper airway muscle tone and respiratory drive. DORAs have a theoretically more favorable profile but are not exempt from concern; the available safety data in OSA are limited. If hypnotics are used in OSA patients, the lowest effective dose, verification of adequate continuous positive airway pressure (CPAP) compliance, and close follow-up are mandatory.
Substance use disorder history: Ramelteon is the safest option — no abuse potential, not scheduled. Low-dose doxepin is a reasonable second choice. Z-drugs and benzodiazepines should generally be avoided.
A clinically important group of agents used as hypnotics operates through mechanisms entirely distinct from GABA-A receptor (GABA-A) modulation or orexin antagonism. These are antidepressants prescribed at doses substantially below their antidepressant threshold, where sedating receptor effects predominate without the full serotonergic profile required for mood effects. Their use is widespread in clinical practice and they occupy an important prescribing niche in patients where controlled substance concerns, dependence risk, or specific comorbidities make scheduled hypnotics problematic.
Low-dose doxepin (Silenor, 3–6 mg) is the only antidepressant with FDA approval specifically for insomnia. At these doses it functions as a selective histamine H1 receptor antagonist without significant anticholinergic, adrenergic, or serotonergic activity, prolonging sleep by reducing nocturnal awakenings through sustained H1 blockade during the sleep period.3 Clinical trials demonstrate significant improvements in sleep maintenance endpoints including wake after sleep onset and total sleep time, with minimal next-day residual sedation. Low-dose doxepin is not a controlled substance and has no established dependence liability — making it particularly useful in patients with substance use disorder histories or in prescribing environments where controlled substance prescribing is administratively burdensome. At these doses it must not be confused with full antidepressant-dose doxepin (75–150 mg), which carries the full tricyclic adverse effect burden including anticholinergic toxicity, orthostatic hypotension, and cardiac conduction effects.
Trazodone (50–150 mg at bedtime) is among the most widely prescribed off-label hypnotics in the United States, used primarily for sleep maintenance insomnia, often in the context of comorbid depression or anxiety. Its hypnotic effects at these doses are mediated primarily through H1 and serotonin 5-5-HT2A serotonin receptor (HT2A) receptor antagonism rather than serotonin reuptake inhibition, promoting sleep without the respiratory depression associated with GABA-active agents. Randomized controlled trial evidence shows modest but consistent improvements in sleep latency and total sleep time.2 Orthostatic hypotension is a clinically relevant adverse effect particularly in elderly patients; priapism is rare but serious in men and requires immediate discontinuation. Trazodone is not scheduled, carries no dependence liability, and is a reasonable first-line pharmacological option in patients with comorbid depression and insomnia where a single agent may address both conditions.
Mirtazapine (7.5–15 mg at bedtime) produces sedation through potent H1 and 5-HT2A receptor antagonism that is paradoxically most pronounced at lower doses — at higher antidepressant doses (30–45 mg), increased noradrenergic activity partially counteracts the sedating H1 effect. Mirtazapine reduces sleep latency and increases slow-wave sleep in clinical studies.2 Its most clinically limiting adverse effect at hypnotic doses is weight gain and increased appetite, mediated by H1 and 5-5-HT2C serotonin receptor (HT2C) antagonism, which restricts its use in patients with metabolic syndrome or obesity. It is particularly useful when sedation, appetite stimulation, and anxiolysis are simultaneously clinically desired — for example in patients with depression, insomnia, anxiety, and unintentional weight loss from cancer or other medical illness. Not scheduled; no dependence liability.
Quetiapine (25–100 mg at bedtime) is an atypical antipsychotic used off-label as a hypnotic with considerable frequency, particularly in psychiatric inpatient settings and in patients with comorbid bipolar disorder, PTSD, or treatment-resistant depression. Its sedating properties at low doses are mediated by H1 and 5-HT2A antagonism. It is not FDA-approved for insomnia as a primary indication and carries the full adverse effect burden of atypical antipsychotics — including metabolic syndrome risk, tardive dyskinesia with long-term use, QTc prolongation, and orthostatic hypotension — which makes it inappropriate as a routine hypnotic for uncomplicated insomnia. Current sleep medicine guidelines do not recommend quetiapine for uncomplicated insomnia disorder, and its use should be reserved for patients with a concurrent psychiatric indication that independently justifies the medication.
Elderly patients represent a particularly important population for dual orexin receptor antagonist (DORA) use given the adverse profile of alternatives in this age group. Both suvorexant and lemborexant have been studied in elderly subjects. A randomized trial of lemborexant versus zolpidem extended-release in older adults demonstrated superior postural stability and driving performance the morning after lemborexant at both 5 mg and 10 mg doses compared to zolpidem ER 6.25 mg, with comparable sleep efficacy.13 This safety profile supports DORAs as preferred pharmacological agents when hypnotic therapy is required in elderly patients. The 5 mg starting dose for lemborexant and the 5–10 mg range for suvorexant are recommended in this population, with upward titration guided by response and tolerability.
In patients with obstructive sleep apnea, DORAs carry a theoretically more favorable profile than GABA-active hypnotics because they do not reduce upper airway muscle tone or blunt the hypoxic arousal response through GABAergic mechanisms. However, this theoretical advantage has not been fully validated in patients with severe untreated OSA, and caution remains warranted. In patients with OSA who are adherent to CPAP therapy, DORAs at standard doses appear clinically reasonable when hypnotic therapy is warranted after confirming adequate CPAP compliance and residual apnea-hypopnea index (AHI).
In patients with post-traumatic stress disorder, the pharmacological profile of DORAs is particularly well-matched to the underlying sleep pathophysiology. PTSD is characterized by disrupted REM sleep, hyperarousal, and trauma-related nightmares. GABA-active hypnotics suppress REM sleep, potentially worsening nightmare recall and interfering with REM-dependent emotional processing believed to be important in trauma recovery. DORAs, by contrast, preserve or modestly increase REM sleep while reducing orexin-mediated wake drive. Preliminary clinical evidence and mechanistic reasoning support DORAs as a pharmacologically rational first-line hypnotic choice in PTSD, and this population is an active area of clinical investigation.11
SCHEDULING AND CONTROLLED STATUS:
Z-drugs (zolpidem, zaleplon, eszopiclone): Schedule IV controlled substances. Prescription Drug Monitoring Program (PDMP) review is required before prescribing in most US states. Refills are subject to schedule IV regulations (typically up to 5 refills within 6 months of original prescription; federal and state rules vary).
Orexin receptor antagonists (suvorexant, lemborexant): Schedule IV controlled substances. PDMP review applies.
Ramelteon and tasimelteon: Not scheduled. No PDMP requirement. This is a clinically significant advantage in prescribing environments where controlled substance prescribing is administratively burdensome or where patient substance use history makes scheduled medications problematic.
INFORMED CONSENT AND PATIENT COUNSELING: For any hypnotic agent, clear counseling should address: expected duration of therapy; rebound insomnia upon discontinuation; avoidance of alcohol (synergistic CNS depression); next-day driving and operating machinery precautions; the black box warning regarding complex sleep behaviors (applicable to all Schedule IV hypnotics); and the primacy of cognitive behavioral therapy for insomnia (CBT-I) as definitive treatment. Patients should be explicitly told that the medication is a bridge, not a cure, and that CBT-I access (including digital CBT-I platforms if in-person therapy is unavailable) is strongly recommended concurrently.
DEPRESCRIBING HYPNOTICS: A growing evidence base supports structured deprescribing of chronic hypnotics, particularly benzodiazepines and Z-drugs in elderly patients. The Canadian Deprescribing Network and multiple clinical guidelines provide structured tapering protocols. For Z-drugs, a 25% dose reduction every 2 weeks, with concurrent CBT-I or sleep hygiene instruction, is supported by randomized trial data showing successful discontinuation rates exceeding 60% with minimal withdrawal symptoms compared to abrupt discontinuation.2 Patients should be warned of expected but self-limited rebound insomnia (typically 1–2 nights worse sleep) immediately after dose reduction, which is qualitatively different from treatment failure.
Understanding how different hypnotic agents alter sleep architecture is clinically important for two reasons: sleep stage disruption has real consequences for daytime function and long-term health, and the differential effects of drug classes on specific sleep stages provide mechanistic rationale for agent selection in patients where sleep quality, not merely sleep quantity, is a treatment priority. The following profiles compare the established sleep architecture effects of each major hypnotic class, with the caveat that most polysomnographic data come from short-term controlled studies in otherwise healthy subjects, and effects in patients with comorbid medical and psychiatric conditions may differ.
Benzodiazepines produce the most pronounced sleep architecture disruption of any commonly used hypnotic class. Through broad GABA-A receptor (GABA-A) potentiation, they reliably suppress slow-wave sleep (N3, delta sleep), which is the most physically restorative stage associated with growth hormone release, immune function, and memory consolidation. They also suppress rapid eye movement (REM) sleep, reducing both REM duration and dream intensity. The net effect is that although benzodiazepines increase total sleep time and reduce sleep onset latency, the sleep produced is pharmacologically altered — lighter, less restorative, and with reduced slow-wave and REM components. Clinically, patients often report feeling unrefreshed despite spending more time asleep, particularly with chronic use. Paradoxically, the spindle-rich N2 sleep that benzodiazepines preserve and increase appears on polysomnography as "sleep" but does not provide the same restorative functions as N3 or REM. Upon discontinuation, rebound increases in both N3 and REM sleep (and intense dreaming associated with REM rebound) are common withdrawal phenomena.1
Z-drugs produce sleep architecture effects that are qualitatively similar to but quantitatively less severe than benzodiazepines, particularly at lower doses where α1 selectivity is most pronounced. At standard therapeutic doses, zolpidem produces minimal suppression of N3 slow-wave sleep, a meaningful distinction from classical benzodiazepines, though this advantage diminishes at higher doses or with extended-release formulations. REM sleep is generally preserved or only modestly affected at standard doses. Eszopiclone, with less pronounced α1 selectivity, produces somewhat more N3 suppression than zolpidem at equivalent sedating doses. Zaleplon, due to its extremely short half-life, has minimal measurable architecture effects beyond the first 1–2 hours of sleep when administered at its standard 10 mg dose. The practical clinical implication is that Z-drugs, particularly immediate-release zolpidem at the lowest effective dose, represent a less architecturally disruptive alternative to benzodiazepines for short-term use, though the advantage is dose- and formulation-dependent rather than absolute.4
Ramelteon and tasimelteon produce essentially no significant disruption of sleep architecture at therapeutic doses. Because their mechanism involves circadian phase-setting rather than direct sedation, they do not suppress N3 or REM sleep, and polysomnographic studies confirm preservation of normal sleep stage distribution with ramelteon use.9 The trade-off is that their hypnotic efficacy — measured as reduction in sleep onset latency — is modest compared to GABA-active agents or DORAs, and they have essentially no effect on sleep maintenance. Over-the-counter (OTC) melatonin at physiological doses (0.3–1 mg) similarly preserves sleep architecture and may modestly advance sleep timing through circadian phase-shifting without pharmacological sedation.
DORAs represent the most favorable sleep architecture profile among pharmacologically active hypnotics. By selectively removing orexin-mediated wake drive, suvorexant and lemborexant reduce sleep onset latency and decrease wake after sleep onset without suppressing any specific sleep stage. Multiple polysomnographic studies confirm that DORAs preserve slow-wave sleep (N3) and may modestly increase REM sleep — potentially through a reduction in wake-promoting signals that normally suppress REM during consolidated sleep periods.11,12 This architecture-preserving property is mechanistically consistent: since DORAs work by removing wake-promoting input rather than pharmacologically inducing sedation, the brain's intrinsic sleep regulatory machinery continues to generate normal sleep architecture. This is in sharp contrast to GABA-active agents, which impose a pharmacologically generated state that resembles sleep neurologically but differs in its stage composition. For clinicians and patients for whom sleep quality and restorative function are the primary treatment goals — particularly patients with cognitive demands, fatigue-related occupational concerns, or conditions where slow-wave sleep has particular therapeutic importance — DORAs represent the pharmacologically superior choice from an architecture standpoint.
Propofol, midazolam, and dexmedetomidine all alter sleep architecture substantially when used for ICU sedation. Propofol-induced sedation produces EEG patterns that share some features with N2/N3 sleep but lacks the cyclical REM-non-rapid eye movement (NREM) architecture of natural sleep; patients sedated with propofol do not cycle through REM sleep in a normal pattern, resulting in REM deprivation during prolonged sedation. Midazolam-based sedation similarly suppresses REM. Dexmedetomidine is the notable exception: its mechanism — inhibiting locus coeruleus noradrenergic activity to produce a state resembling natural N2 sleep — generates an EEG and behavioral state that more closely approximates physiological sleep than any other IV sedative, with preserved arousal pathways and spontaneous sleep spindles on EEG. This unique neurobiological profile may partly explain the lower delirium rates observed with dexmedetomidine in clinical trials, as delirium in the ICU is strongly associated with circadian rhythm disruption and REM sleep deprivation during critical illness.14
Winsky-Sommerer R. Role of GABA-A receptors in the physiology and pharmacology of sleep. Eur J Neurosci. 2009;29(9):1779–1794.
doi:10.1111/j.1460-9568.2009.06716.xRiemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26(6):675–700.
doi:10.1111/jsr.12594Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacological treatment of chronic insomnia in adults. J Clin Sleep Med. 2017;13(2):307–349.
doi:10.5664/jcsm.6470Sanna E, Busonero F, Talani G, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA-A receptor subtypes. Eur J Pharmacol. 2002;451(2):103–110.
doi:10.1016/S0014-2999(02)02191-XUS Food and Drug Administration. FDA Drug Safety Communication: Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs. January 10, 2013.
Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet. 2004;43(4):227–238.
doi:10.2165/00003088-200443040-00002US Food and Drug Administration. FDA Drug Safety Communication: FDA adds boxed warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia medicines. April 30, 2019.
American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052–2081.
doi:10.1111/jgs.18372Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005;48(2):301–310.
doi:10.1016/j.neuropharm.2004.09.007Vanda Pharmaceuticals. Hetlioz (tasimelteon) [prescribing information]. Washington, DC: Vanda Pharmaceuticals; 2020.
Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci. 2007;8(3):171–181.
doi:10.1038/nrn2092Herring WJ, Connor KM, Ivgy-May N, et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry. 2016;79(2):136–148.
doi:10.1016/j.biopsych.2014.10.003Murphy P, Kumar D, Zammit G, Rosenberg R, Moline M. Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants. J Clin Sleep Med. 2020;16(5):765–773.
doi:10.5664/jcsm.8294Trompeo AC, Vidi Y, Locane MD, et al. Sleep disturbances in the critically ill patients: role of delirium and sedative agents. Minerva Anestesiol. 2011;77(6):604–612.